Rami Vanguri
Overview
Explore the profile of Rami Vanguri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
502
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barcia Duran J, Das D, Gildea M, Amadori L, Gourvest M, Kaur R, et al.
Nat Cardiovasc Res
. 2024 Nov;
3(12):1482-1502.
PMID: 39613875
Immune checkpoint inhibitor (ICI) therapies can increase the risk of cardiovascular events in survivors of cancer by worsening atherosclerosis. Here we map the expression of immune checkpoints (ICs) within human...
2.
Rumberger J, Greenwald N, Ranek J, Boonrat P, Walker C, Franzen J, et al.
bioRxiv
. 2024 Jun;
PMID: 38895405
Multiplexed imaging offers a powerful approach to characterize the spatial topography of tissues in both health and disease. To analyze such data, the specific combination of markers that are present...
3.
El Homsi M, Bane O, Fauveau V, Hectors S, Violi N, Sylla P, et al.
Abdom Radiol (NY)
. 2023 Dec;
49(3):791-800.
PMID: 38150143
Purpose: To assess the role of pretreatment multiparametric (mp)MRI-based radiomic features in predicting pathologic complete response (pCR) of locally advanced rectal cancer (LARC) to neoadjuvant chemoradiation therapy (nCRT). Methods: This...
4.
Vazquez-Garcia I, Uhlitz F, Ceglia N, Lim J, Wu M, Mohibullah N, et al.
Nature
. 2022 Dec;
612(7941):778-786.
PMID: 36517593
High-grade serous ovarian cancer (HGSOC) is an archetypal cancer of genomic instability patterned by distinct mutational processes, tumour heterogeneity and intraperitoneal spread. Immunotherapies have had limited efficacy in HGSOC, highlighting...
5.
Ghahremani P, Li Y, Kaufman A, Vanguri R, Greenwald N, Angelo M, et al.
Nat Mach Intell
. 2022 Sep;
4(4):401-412.
PMID: 36118303
Reporting biomarkers assessed by routine immunohistochemical (IHC) staining of tissue is broadly used in diagnostic pathology laboratories for patient care. To date, clinical reporting is predominantly qualitative or semi-quantitative. By...
6.
Boehm K, Aherne E, Ellenson L, Nikolovski I, Alghamdi M, Vazquez-Garcia I, et al.
Nat Cancer
. 2022 Jun;
3(6):723-733.
PMID: 35764743
Patients with high-grade serous ovarian cancer suffer poor prognosis and variable response to treatment. Known prognostic factors for this disease include homologous recombination deficiency status, age, pathological stage and residual...
7.
Understanding the impact of chemotherapy on the immune landscape of high-grade serous ovarian cancer
Vanguri R, Benhamida J, Young J, Li Y, Zivanovic O, Chi D, et al.
Gynecol Oncol Rep
. 2022 Feb;
39:100926.
PMID: 35146104
Objectives: We quantitatively characterized the change in temporospatial expression of repressive and stimulatory checkpoints across immune cell populations in the tumor microenvironment in a cohort of high grade serous ovarian...
8.
Boehm K, Khosravi P, Vanguri R, Gao J, Shah S
Nat Rev Cancer
. 2021 Oct;
22(2):114-126.
PMID: 34663944
Advances in quantitative biomarker development have accelerated new forms of data-driven insights for patients with cancer. However, most approaches are limited to a single mode of data, leaving integrated approaches...
9.
Liu Y, Liu Y, Vanguri R, Litwiller D, Liu M, Hsu H, et al.
J Digit Imaging
. 2021 Sep;
34(5):1199-1208.
PMID: 34519954
We developed a deep learning-based super-resolution model for prostate MRI. 2D T2-weighted turbo spin echo (T2w-TSE) images are the core anatomical sequences in a multiparametric MRI (mpMRI) protocol. These images...
10.
Moore M, Friesner I, Rizk E, Fullerton B, Mondal M, Trager M, et al.
Sci Rep
. 2021 Feb;
11(1):2809.
PMID: 33531581
Accurate prognostic biomarkers in early-stage melanoma are urgently needed to stratify patients for clinical trials of adjuvant therapy. We applied a previously developed open source deep learning algorithm to detect...